| [1] |
Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial[J]. Lancet, 2021, 398(10294): 27-40. DOI: 10.1016/S0140-6736(21)00797-2.
pmid: 34102137
|
| [2] |
Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics[J]. Lancet Oncol, 2017, 18(3): e143-e152. DOI: 10.1016/S1470-2045(17)30074-8.
|
| [3] |
Queirolo P, Spagnolo F. Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: a systematic review[J]. Cancer Treat Rev, 2017, 59: 71-78. DOI: 10.1016/j.ctrv.2017.07.002.
pmid: 28756306
|
| [4] |
Park HJ, Kim KW, Pyo J, et al. Incidence of pseudoprogression during immune checkpoint inhibitor therapy for solid tumors:asystematic review and meta-analysis[J]. Radiology, 2020, 297(1): 87-96. DOI: 10.1148/radiol.2020200443.
|
| [5] |
Billan S, Kaidar-Person O, Gil Z. Treatment after progression in the era of immunotherapy[J]. Lancet Oncol, 2020, 21(10): e463-e476. DOI: 10.1016/S1470-2045(20)30328-4.
|
| [6] |
Michalarea V, Fontana E, Garces AI, et al. Pseudoprogression on treatment with immune-checkpoint inhibitors in patients with gastrointestinal malignancies: case series and short literature review[J]. Curr Probl Cancer, 2019, 43(5): 487-494. DOI: 10.1016/j.currproblcancer. 2019.01.008.
|
| [7] |
Martin-Romano P, Castanon E, Ammari S, et al. Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types[J]. Cancer Med, 2020, 9(8): 2643-2652. DOI: 10.1002/cam4. 2797.
|
| [8] |
Nishino M, Giobbie-Hurder A, Manos MP, et al. Immune-related tumor response dynamics in melanoma patients treated with pembrolizumab:identifying markers for clinical outcome and treatment decisions[J]. Clin Cancer Res, 2017, 23(16): 4671-4679. DOI: 10.1158/1078-0432.CCR-17-0114.
pmid: 28592629
|
| [9] |
Fujimoto D, Yoshioka H, Kataoka Y, et al. Pseudoprogression in previously treated patients with non-small cell lung cancer who received nivolumab monotherapy[J]. J Thorac Oncol, 2019, 14(3): 468-474. DOI: 10.1016/j.jtho.2018.10.167.
pmid: 30468872
|
| [10] |
Di Giacomo AM, Danielli R, Guidoboni M, et al. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases[J]. Cancer Immunol Immunother, 2009, 58(8): 1297-1306. DOI: 10.1007/s00262-008-0642-y.
pmid: 19139884
|
| [11] |
Tanizaki J, Hayashi H, Kimura M, et al. Report of two cases of pseudoprogression in patients with non-small cell lung cancer treated with nivolumab-including histological analysis of one case after tumor regression[J]. Lung Cancer, 2016, 102: 44-48. DOI: 10.1016/j.lungcan.2016.10.014.
pmid: 27987588
|
| [12] |
Frelaut M, du Rusquec P, de Moura A, et al. Pseudoprogression and hyperprogression as new forms of response to immunotherapy[J]. Bio Drugs, 2020, 34(4): 463-476. DOI: 10.1007/s40259-020-00425-y.
|
| [13] |
Tabei T, Tsuura Y, Kobayashi K. Pseudoprogression: a case of metastatic renal clear cell carcinoma treated with nivolumab[J]. Pathol Int, 2018, 68(11): 627-629. DOI: 10.1111/pin.12714.
pmid: 30151940
|
| [14] |
Jia W, Gao Q, Han A, et al. The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy[J]. Cancer Biol Med, 2019, 16(4): 655-670. DOI: 10. 20892/j.issn.2095-3941.2019.0144.
pmid: 31908886
|
)
